Navigation Links
Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
Date:2/17/2012

EAST BRUNSWICK, N.J., Feb. 17, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Citi 2012 Global Health Care Conference on Tuesday, February 28, 2012 at 8:30 AM Eastern Time.  The conference will be held at the Waldorf Astoria Hotel in New York City.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT - GContact: Mary Coleman

Carney NoensieSavient Pharmaceuticals, Inc.

Burns McClellaninformation@savient.com  

cnoensie@burnsmc.com(732) 418-9300

(212) 213-0006 


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
2. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
3. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
4. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
5. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
6. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
8. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
9. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
10. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
11. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... England , March 28, 2017 ... collaborative research with Cambridge ... Therapeutics Consortium   The Milner Therapeutics Institute today ... Consortium. Elysium Health has committed significant investment for collaborative projects ... the next four years. This is the first major research ...
(Date:3/27/2017)... , March 27, 2017 ... better understand Eli Lilly and its partnering interests and activities ... 2010 report provides an in-depth insight into the partnering activity ... On demand company reports are prepared upon purchase to ... company data. The report will be delivered in ...
(Date:3/27/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced ... efficacy studies. The company is harnessing the power of ... A, in an effort to find a better treatment ... 4 weeks of treatment in transgenic mice, the lead ... a full toxicology report of various organs. Cytotoxic T-cells ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Columbus OH. ... selected as one of few medical professionals in the country to sit on the ... of Juvly Aesthetics, in just 2 years Dr. Harper helped propel the clinic from ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant ... Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System to ... adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. ...
(Date:3/28/2017)... ... , ... With expansion and efficiency in mind, Patten Seed Company completed relocation ... plant opened in Marshallville in 2006, and a bagging and shipping facility has been ... of Patten Seed operations to the Middle Georgia location from their previous home in ...
(Date:3/28/2017)... ... ... Thank you to all who attended Capio Partners Winter 2017 Healthcare Leadership Symposium in ... and offered an opportunity to collaborate and network with healthcare colleagues across the United ... gathered for a lively discussion on trends and issues that healthcare leaders will face ...
(Date:3/28/2017)... ... ... Bacteria and fungi are probably not the first ingredients that come to mind when thinking ... in your diet can actually improve health outcomes. And the good news is they may ... a new peer-reviewed paper led by Maria Marco, Ph.D. , University of ...
Breaking Medicine News(10 mins):